CRL : Analysis & Opinions

  1. ICON (ICLR) Now a Strong Buy: Should It Be in Your Portfolio? ...

    December 16, 2014
    ICON has been witnessing rising earnings estimates on the back of a new FDA project and an increased guidance for fiscal ...
  2. Spot Big Dividend Hikes With This Value Metric

    October 25, 2013
    Individual investors and private equity firms often target companies with great yields. But they are talking about two different ...
  3. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  4. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  5. PPD Goes Private

    October 6, 2011
    PPD's acceptance of a low buyout bid raises questions about the CRO industry.
  6. Four Small Caps From The Perkins Portfolio

    November 4, 2010
    Perkins' small-cap value fund's three- and five-year performance is excellent, and investors should take note.
  7. Playing Big Pharma With CROs

    July 6, 2010
    Investors looking to play the growth in R&D spending for human drugs should consider CROs.
  8. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
Trading Center